Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Código QR

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole

Phyllis M Salzman,1 Arash Raoufinia,2 Susan Legacy,3 Pedro Such,4 Anna Eramo5 1Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, 2Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salzman PM, Raoufinia A, Legacy S, Such P, Eramo A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	long-acting injectable aripiprazole plasma concentrations dosing schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ca5b79ce43c04b4b963ea261d0ea7795
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
por: McConnell SA, et al.
Publicado: (2017)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland T, et al.
Publicado: (2019)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
por: Natalia N. Petrova, et al.
Publicado: (2020)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

Aripiprazole for late-life schizophrenia
por: Jeffrey Rado, et al.
Publicado: (2010)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic M, et al.
Publicado: (2018)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
por: Junli Zhu, et al.
Publicado: (2021)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment
por: Madera J, et al.
Publicado: (2019)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Dhiren Singh, et al.
Publicado: (2009)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand E, et al.
Publicado: (2016)

Low-dose aripiprazole for refractory burning mouth syndrome
por: Umezaki Y, et al.
Publicado: (2016)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome L, et al.
Publicado: (2019)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

DEVELOPMENT OF A SIMPLE AND SPECIFIC UHPLC ASSAY FOR THE DETERMINATION OF ARIPIPRAZOLE AND DEHYDROARDPDPRAZOLE IN RAT PLASMA
por: YENICELI UĞUR,DUYGU, et al.
Publicado: (2015)

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
por: Zhi P, et al.
Publicado: (2018)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu LL, et al.
Publicado: (2019)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing®): a case report
por: Shao Q, et al.
Publicado: (2015)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations
por: Mayerova M, et al.
Publicado: (2018)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi T, et al.
Publicado: (2016)

Usability of a novel digital medicine system in adults with schizophrenia treated with sensor-embedded tablets of aripiprazole
por: Peters-Strickland T, et al.
Publicado: (2016)

Long-acting reversible hormonal contraception
por: N. E. Dahan-Farkas, et al.
Publicado: (2016)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda A, et al.
Publicado: (2018)

Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
por: Subramanian Madhusoodanan, et al.
Publicado: (2008)

The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing
por: Lefan Jin, et al.
Publicado: (2021)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Alcohol dependence is formed on the background of violations of mental adaptation
por: T. V. Agibalova, et al.
Publicado: (2013)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)